1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

US FDA Dives Back Into Opioid Reviews Under New Division Leadership

 
• By Michael McCaughan

Four new pain drug formulations are heading to advisory committees in January. The meetings will also feature new FDA leadership in the pain/addiction review division following the retirement of Sharon Hertz.

People running from dangerous pills

The US Food & Drug Administration is diving back into the thorny area of novel opioid reviews with a series of four advisory committee reviews of products offering different twists on potential avenues to improve pain treatment in the context of the opioid abuse crisis.

FDA has scheduled four products for review by its Anesthetic & Analgesic Drugs Advisory Committee across three days (14-16 January)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers